Norton Rose Fulbright advises on ADQ’s acquisition of Birgi Mefar Group

Global law firm Norton Rose Fulbright advised the shareholders of Turkish pharmaceuticals company Birgi Mefar Group (BMG) on the sale of 100% of its shares to Abu Dhabi investment and holding company ADQ.

BMG is one of Turkey’s leading producers of sterile injectable products, such as vials and pre-filled syringes for vaccines, and has operations in over 30 countries. ADQ is an Abu Dhabi-based investment and holding company with investments in sectors including energy and utilities, food and agriculture, healthcare and life sciences, and mobility and logistics.

Norton Rose Fulbright’s team, led by corporate partners Ayse Yüksel Mahfoud and Claire O’Donnell - with additional input from partner Matt Foster - worked in collaboration with Pekin Bayar Mizrahi, Norton Rose Fulbright’s alliance firm in Turkey, on the transaction.

The deal, which was signed on 13 June and is now subject to regulatory approvals, will see BMG join ADQ’s Healthcare and Life Sciences Portfolio. It will provide ADQ with exposure to a fast-growing market of injectables and high-value treatments, such as vaccines, as well as access to a wide customer network ranging from large multinationals to local and regional players.

Ayse Yüksel Mahfoud, global head of corporate, M&A and securities at Norton Rose Fulbright, said:  “This acquisition by ADQ of one of the largest pharmaceutical companies in Turkey is the latest in a series of important cross-border deals to take place in this rapidly evolving market.

“We were delighted to work in collaboration with Pekin Bayar Mizrahi on this complex deal in the Turkish healthcare sector, which involved a private equity exit by two non-Turkish private equity funds and a direct investment into Turkey by a sovereign wealth fund.” 

Norton Rose Fulbright’s award-winning corporate, M&A and securities team advises corporations and financial institutions across the full spectrum of industry matters. These include public takeovers, private M&A, joint ventures, disposals, debt and equity capital markets, governance, general commercial and corporate advisory matters.